Human B lymphocytes were used as immunogen for this recombinant CD45RB antibody.
CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45RB is expressed on mature B-lymphocytes and the majority of lymphomas and leukemias of B-cell origin. This antigen is also expressed on the surface of cells of myeloid lineage.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Flow cytometry: 1-2ug/10 6 cells,Immunofluorescence: 1-2ug/ml,Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)
Application Notes:
The stated application concentrations are suggested starting points. Titration of the recombinant CD45RB antibody may be required due to differences in protocols and secondary/substrate sensitivity.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
